AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
radium Ra 223 dichloride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4800 | 444811-40-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 67 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 15, 2013 | FDA | BAYER HLTHCARE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Prostatic specific antigen increased | 1334.37 | 32.11 | 355 | 7555 | 16570 | 42596855 |
| Metastases to bone | 767.62 | 32.11 | 224 | 7686 | 14585 | 42598840 |
| Metastases to liver | 431.89 | 32.11 | 148 | 7762 | 16178 | 42597247 |
| Bone pain | 255.29 | 32.11 | 112 | 7798 | 23680 | 42589745 |
| Prostate cancer metastatic | 247.26 | 32.11 | 78 | 7832 | 6551 | 42606874 |
| General physical health deterioration | 238.73 | 32.11 | 208 | 7702 | 151038 | 42462387 |
| Anaemia | 228.05 | 32.11 | 269 | 7641 | 280009 | 42333416 |
| Prostate cancer | 201.82 | 32.11 | 117 | 7793 | 44526 | 42568899 |
| Metastases to lymph nodes | 192.62 | 32.11 | 63 | 7847 | 5935 | 42607490 |
| Spinal cord compression | 188.31 | 32.11 | 57 | 7853 | 4167 | 42609258 |
| Osteonecrosis of jaw | 170.32 | 32.11 | 79 | 7831 | 18970 | 42594455 |
| Haemoglobin decreased | 161.67 | 32.11 | 158 | 7752 | 132313 | 42481112 |
| Metastasis | 161.56 | 32.11 | 52 | 7858 | 4653 | 42608772 |
| Death | 139.27 | 32.11 | 283 | 7627 | 470902 | 42142523 |
| Prostate cancer stage IV | 129.37 | 32.11 | 38 | 7872 | 2502 | 42610923 |
| Disease progression | 117.99 | 32.11 | 139 | 7771 | 143517 | 42469908 |
| Metastases to spine | 117.99 | 32.11 | 37 | 7873 | 3040 | 42610385 |
| Platelet count decreased | 111.99 | 32.11 | 133 | 7777 | 138448 | 42474977 |
| Laboratory test abnormal | 111.13 | 32.11 | 63 | 7847 | 22915 | 42590510 |
| Metastases to lung | 110.29 | 32.11 | 50 | 7860 | 11374 | 42602051 |
| Pathological fracture | 98.33 | 32.11 | 37 | 7873 | 5256 | 42608169 |
| Full blood count abnormal | 81.54 | 32.11 | 57 | 7853 | 29819 | 42583606 |
| Malignant neoplasm progression | 80.88 | 32.11 | 100 | 7810 | 108300 | 42505125 |
| Pancytopenia | 80.53 | 32.11 | 104 | 7806 | 117639 | 42495786 |
| Bone marrow failure | 78.54 | 32.11 | 58 | 7852 | 33035 | 42580390 |
| Pain | 77.70 | 32.11 | 152 | 7758 | 244696 | 42368729 |
| Thrombocytopenia | 71.40 | 32.11 | 127 | 7783 | 190152 | 42423273 |
| Malaise | 70.06 | 32.11 | 134 | 7776 | 212022 | 42401403 |
| Blood test abnormal | 66.76 | 32.11 | 37 | 7873 | 12869 | 42600556 |
| Metastases to soft tissue | 62.66 | 32.11 | 15 | 7895 | 444 | 42612981 |
| Hospitalisation | 60.98 | 32.11 | 72 | 7838 | 74258 | 42539167 |
| Metastases to central nervous system | 59.98 | 32.11 | 32 | 7878 | 10323 | 42603102 |
| Metastases to bone marrow | 59.91 | 32.11 | 15 | 7895 | 537 | 42612888 |
| Decreased appetite | 58.87 | 32.11 | 118 | 7792 | 193019 | 42420406 |
| Blood alkaline phosphatase increased | 56.31 | 32.11 | 48 | 7862 | 33549 | 42579876 |
| Hormone-refractory prostate cancer | 55.45 | 32.11 | 16 | 7894 | 988 | 42612437 |
| Prostate cancer recurrent | 54.25 | 32.11 | 16 | 7894 | 1067 | 42612358 |
| Cancer pain | 52.29 | 32.11 | 21 | 7889 | 3546 | 42609879 |
| Traumatic fracture | 49.17 | 32.11 | 12 | 7898 | 386 | 42613039 |
| Bone marrow infiltration | 43.90 | 32.11 | 10 | 7900 | 237 | 42613188 |
| Femur fracture | 42.34 | 32.11 | 25 | 7885 | 9787 | 42603638 |
| Asthenia | 41.34 | 32.11 | 130 | 7780 | 280663 | 42332762 |
| Haematotoxicity | 39.74 | 32.11 | 25 | 7885 | 10960 | 42602465 |
| Blood alkaline phosphatase decreased | 37.53 | 32.11 | 12 | 7898 | 1049 | 42612376 |
| Spinal compression fracture | 37.45 | 32.11 | 21 | 7889 | 7462 | 42605963 |
| Fracture | 35.90 | 32.11 | 21 | 7889 | 8082 | 42605343 |
| Bladder tamponade | 34.49 | 32.11 | 10 | 7900 | 628 | 42612797 |
| Myelosuppression | 34.49 | 32.11 | 40 | 7870 | 40421 | 42573004 |
| Pelvic pain | 33.80 | 32.11 | 15 | 7895 | 3239 | 42610186 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Prostatic specific antigen increased | 1116.80 | 36.87 | 227 | 5290 | 12284 | 110571498 |
| Metastases to bone | 496.96 | 36.87 | 141 | 5376 | 31231 | 110552551 |
| Metastases to liver | 286.19 | 36.87 | 95 | 5422 | 35291 | 110548491 |
| Anaemia | 261.41 | 36.87 | 216 | 5301 | 546870 | 110036912 |
| Prostate cancer metastatic | 221.41 | 36.87 | 51 | 5466 | 4892 | 110578890 |
| Prostate cancer | 189.23 | 36.87 | 71 | 5446 | 37570 | 110546212 |
| Bone pain | 167.31 | 36.87 | 76 | 5441 | 65057 | 110518725 |
| Osteonecrosis of jaw | 149.00 | 36.87 | 64 | 5453 | 47953 | 110535829 |
| Platelet count decreased | 148.54 | 36.87 | 109 | 5408 | 230334 | 110353448 |
| Haemoglobin decreased | 145.52 | 36.87 | 111 | 5406 | 248616 | 110335166 |
| Metastases to lymph nodes | 140.18 | 36.87 | 45 | 5472 | 14987 | 110568795 |
| Death | 132.67 | 36.87 | 168 | 5349 | 698701 | 109885081 |
| General physical health deterioration | 117.10 | 36.87 | 124 | 5393 | 425171 | 110158611 |
| Laboratory test abnormal | 99.30 | 36.87 | 47 | 5470 | 44032 | 110539750 |
| Metastases to spine | 98.02 | 36.87 | 27 | 5490 | 5316 | 110578466 |
| Thrombocytopenia | 96.42 | 36.87 | 102 | 5415 | 348783 | 110234999 |
| Pancytopenia | 93.68 | 36.87 | 80 | 5437 | 209533 | 110374249 |
| Metastases to lung | 92.68 | 36.87 | 37 | 5480 | 23026 | 110560756 |
| Spinal cord compression | 88.79 | 36.87 | 27 | 5490 | 7525 | 110576257 |
| Pathological fracture | 88.03 | 36.87 | 30 | 5487 | 12002 | 110571780 |
| Prostate cancer stage IV | 86.92 | 36.87 | 21 | 5496 | 2467 | 110581315 |
| Metastasis | 82.21 | 36.87 | 26 | 5491 | 8241 | 110575541 |
| Hospitalisation | 81.85 | 36.87 | 63 | 5454 | 142430 | 110441352 |
| Metastases to soft tissue | 75.60 | 36.87 | 15 | 5502 | 704 | 110583078 |
| Full blood count abnormal | 66.69 | 36.87 | 39 | 5478 | 56013 | 110527769 |
| Bone marrow failure | 65.55 | 36.87 | 39 | 5478 | 57809 | 110525973 |
| Decreased appetite | 63.77 | 36.87 | 97 | 5420 | 475749 | 110108033 |
| Blood test abnormal | 62.92 | 36.87 | 30 | 5487 | 28524 | 110555258 |
| Prostate cancer recurrent | 59.89 | 36.87 | 13 | 5504 | 949 | 110582833 |
| Cancer pain | 57.93 | 36.87 | 19 | 5498 | 6753 | 110577029 |
| Blood alkaline phosphatase increased | 48.83 | 36.87 | 35 | 5482 | 70900 | 110512882 |
| Hormone-refractory prostate cancer | 44.00 | 36.87 | 10 | 5507 | 900 | 110582882 |
| Metastases to central nervous system | 41.39 | 36.87 | 21 | 5496 | 22796 | 110560986 |
| Malignant neoplasm progression | 39.39 | 36.87 | 46 | 5471 | 174521 | 110409261 |
| Malaise | 37.84 | 36.87 | 95 | 5422 | 671724 | 109912058 |
| Asthenia | 37.32 | 36.87 | 96 | 5421 | 688903 | 109894879 |
| Hyphaema | 36.91 | 36.87 | 9 | 5508 | 1098 | 110582684 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V10XX03 | VARIOUS THERAPEUTIC RADIOPHARMACEUTICALS OTHER THERAPEUTIC RADIOPHARMACEUTICALS Various therapeutic radiopharmaceuticals |
| MeSH PA | D000970 | Antineoplastic Agents |
| CHEBI has role | CHEBI:35232 | radiopharmaceuticals |
| CHEBI has role | CHEBI:35610 | antineoplastic agents |
Related Drugs by ATC class:
V10XX Various therapeutic radiopharmaceuticals 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Malignant tumor of prostate | indication | 399068003 | DOID:10283 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4037730 | VANDF |
| CHEMBL2107816 | ChEMBL_ID |
| C581106 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB08913 | DRUGBANK_ID |
| RJ00KV3VTG | UNII |
| 1424174 | RXNORM |
| 203076 | MMSL |
| 29462 | MMSL |
| d08101 | MMSL |
| 015032 | NDDF |
| C3541342 | UMLSCUI |
| CHEBI:74895 | CHEBI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Xofigo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50419-208 | INJECTION | 30 uCi | INTRAVENOUS | NDA | 27 sections |